Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders

Merger Details - Titan will engage in a reverse merger with KE Sdn Bhd, resulting in Titan becoming minority stockholders of the combined company [2] - Post-merger, non-insider Titan stockholders will own only 13% of the combined companies, while Dato' Seow Gim Shen, Chairman and CEO of Titan, holds 47.4% of KE's outstanding shares [2] - The transaction agreement imposes significant penalties on Titan if it accepts a competing bid, limiting competing transactions [2] Investigation and Shareholder Concerns - Ademi LLP is investigating Titan for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn Bhd [1] - The investigation focuses on whether Titan's board of directors is fulfilling its fiduciary duties to all shareholders [3] - Titan insiders are set to receive substantial benefits as part of change of control arrangements, raising concerns about fairness to non-insider shareholders [2] Legal Context - Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights [4] - The firm is encouraging Titan common stock owners to contact them for additional information regarding the investigation [3]